Vis enkel innførsel

dc.contributor.authorKnapskog, Anne Brita
dc.contributor.authorHenjum, Kristi
dc.contributor.authorIdland, Ane-Victoria
dc.contributor.authorEldholm, Rannveig Sakshaug
dc.contributor.authorPersson, Karin Ester Torun
dc.contributor.authorSaltvedt, Ingvild
dc.contributor.authorWatne, Leiv
dc.contributor.authorEngedal, Knut
dc.contributor.authorNilsson, Lars N.G.
dc.date.accessioned2021-01-18T14:37:21Z
dc.date.available2021-01-18T14:37:21Z
dc.date.created2020-10-07T09:39:38Z
dc.date.issued2020
dc.identifier.citationScientific Reports. 2020, 10 1-10.en_US
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/11250/2723539
dc.description.abstractTriggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor expressed by microglia. Its cleaved fragments, soluble TREM2 (sTREM2), can be measured in the cerebrospinal fluid (CSF). Previous studies indicate higher CSF sTREM2 in symptomatic AD; however most of these studies have included biomarker positive AD cases and biomarker negative controls. The aim of the study was to explore potential differences in the CSF level of sTREM2 and factors associated with an increased sTREM2 level in patients diagnosed with mild cognitive impairment (MCI) or dementia due to AD compared with cognitively unimpaired controls as judged by clinical symptoms and biomarker category (AT). We included 299 memory clinic patients, 62 (20.7%) with AD-MCI and 237 (79.3%) with AD dementia, and 113 cognitively unimpaired controls. CSF measures of the core biomarkers were applied to determine AT status. CSF sTREM2 was analyzed by ELISA. Patients presented with comparable CSF sTREM2 levels as the cognitively unimpaired (9.6 ng/ml [SD 4.7] versus 8.8 ng/ml [SD 3.6], p = 0.27). We found that CSF sTREM2 associated with age-related neuroinflammation and tauopathy irrespectively of amyloid β, APOE ε4 status or gender. The findings were similar in both symptomatic and non-symptomatic individuals.en_US
dc.language.isoengen_US
dc.publisherNature Researchen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleCerebrospinal fluid sTREM2 in Alzheimer’s disease: comparisons between clinical presentation and AT classificationen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-10en_US
dc.source.volume10en_US
dc.source.journalScientific Reportsen_US
dc.identifier.doi10.1038/s41598-020-72878-8
dc.identifier.cristin1837797
dc.description.localcode© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International Licenseen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal